REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial (REVERENT)
Primary Purpose
Hypertension, High Blood Pressure Variability
Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Nifedipine GITS
Ramipril
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Blood pressure variability, Home systolic blood pressure, Organ damage, Nifedipine GITS, Ramipril
Eligibility Criteria
Inclusion Criteria:
- Male and female subjects
- Age 35-75 years
- Clinic systolic BP ≥140 mmHg and/or diastolic BP ≥ 90 mmHg (under no antihypertensive treatment)
- Daytime BP on ambulatory BP monitoring (ABPM) ≥135 mmHg systolic and/or ≥85 mmHg diastolic (under no antihypertensive treatment)
- Home SBP standard deviation (SD) >7 mmHg and/or daytime ambulatory SBP SD >12 mmHg
- Patients may be included if untreated or, if treated with one antihypertensive drug or two drugs in low doses, after 2 weeks' washout period
- Written informed consent to participate in the study
Exclusion Criteria:
- Subjects treated with ≥ 2 antihypertensive drugs (except those on two drugs in low doses)
- Treated subjects with on-treatment clinic BP ≥160 mmHg systolic and/or 100 mmHg diastolic
- Treated antihypertensive subjects in whom withdrawal of treatment is deemed unethical by the investigator (e.g. because of the existence of compelling indications other than hypertension for continuous use of previously used antihypertensive agent)
- Contraindications to study treatments as detailed in the relative Summaries of Medical Product Characteristics for ramipril (hypersensitivity to ramipril or any of the excipients or any other ACE inhibitor, history of angioneurotic oedema, extracorporeal treatments leading to contact of blood with negatively charged surfaces, significant bilateral renal artery stenosis or renal artery stenosis in a single functioning kidney, second and third trimesters of pregnancy, lactation, haemodynamically relevant renal artery stenosis, hypotensive or haemodynamically unstable patients) or nifedipine GITS (known hypersensitivity to nifedipine or to any of the excipients, pregnancy before week 20 and during breastfeeding, cardiovascular shock, concomitant treatment with rifampicin, patients with a Kock pouch)
- Cardiovascular diseases other than hypertension (coronary heart disease, heart failure or left ventricular systolic dysfunction of any degree, atrial fibrillation or frequent arrhythmias, valvular or congenital heart disease, cardiomyopathies, cerebrovascular disease, peripheral artery disease, aortic aneurysm)
- Chronic kidney disease
- Suspected or confirmed secondary hypertension
- Diabetes mellitus
- Subjects with conditions other than those mentioned above, where compelling indications for the use of any specific class of antihypertensive medication exist, according to current (e.g. European Society of Cardiology) guidelines
- Other conditions deemed relevant by the investigator (including respiratory disorders, liver disease, renal disease, thyroid disorders)
- BMI ≥35 kg/m2
- Known severe obstructive sleep apnea (apnea-hypopnea index > 30 or use of CPAP)
- Premenopausal women not using effective contraceptive methods
- Elevated probability of noncompliance with the study procedures
Sites / Locations
- Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital Shanghai Institute of Hypertension, Shanghai Jiaotong University School of Medicine
- Hypertension Center, Third University Department of Medicine, Sotiria Hospital
- Istituto Auxologico Italiano
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Nifedipine GITS 30 mg slow release
Ramipril 10 mg
Arm Description
Nifedipine GITS 30 mg slow release in tablets.
Ramipril 10 mg in tablets.
Outcomes
Primary Outcome Measures
Variability (standard deviation) of home systolic blood pressure at final visit
Secondary Outcome Measures
Variability (standard deviation) of home diastolic blood pressure measured at final visit
Short term 24h variability of systolic blood pressure at final visit (24h weighted standard deviation)
Short term 24h variability of diastolic blood pressure at final visit (24h weighted standard deviation)
Visit-to-visit variability (standard deviation) of systolic blood pressure assessed over the three last visits
Visit-to-visit variability (standard deviation) of diastolic blood pressure assessed over the three last visits
Mean 24 hour systolic blood pressure at final visit
Mean 24 hour diastolic blood pressure at final visit
Sokolow index at the end of the extension study
Cornell voltage duration index at the end of the extension study
Left ventricular mass index at the end of the extension study
Microalbuminuria (albumin-creatinine ratio) at the end of the extension study
Estimated glomerular filtration rate (eGFR, by CKD-EPI formula) at the end of the extension study
Carotid-femoral pulse wave velocity (cfPWV) at the end of the extension study
Full Information
NCT ID
NCT02499822
First Posted
July 10, 2015
Last Updated
September 29, 2021
Sponsor
Istituto Auxologico Italiano
Collaborators
Bayer
1. Study Identification
Unique Protocol Identification Number
NCT02499822
Brief Title
REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial
Acronym
REVERENT
Official Title
Short - Medium and Long Term Blood Pressure Variability in Essential Hypertensive Patients Treated With Nifedipine GITS or Ramipril - a Randomized Trial
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
October 2015 (undefined)
Primary Completion Date
July 3, 2020 (Actual)
Study Completion Date
November 1, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Istituto Auxologico Italiano
Collaborators
Bayer
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is
to compare the effects of nifedipine GITS and ramipril on blood pressure variability in subjects with elevated blood pressure variability.
to assess whether the degree of treatment-induced changes in blood pressure variability, is related to the degree of regression (or progression) of organ damage in heart, kidneys and carotid arteries.
Detailed Description
Elevated blood pressure variability (BPV) is associated with adverse cardiovascular outcomes and organ damage in hypertensive subjects. An antihypertensive treatment able to reduce BPV independently of BP lowering effect might thus provide additional protection in terms of cardiovascular risk in subjects with elevated BPV, independently on its effect of BP itself. However, data on the effects of different classes of antihypertensive drugs on BPV are limited and inconsistent. Some studies have suggested a possible usefulness of calcium antagonists in this setting. Based on the above considerations the investigators hypothesize that a calcium channel blocker nifedipine GITS, will provide a greater BPV lowering effect, when compared with ramipril, independently from the reduction in mean BP level. Based on the above considerations, the primary objective of this study is to compare the effects of nifedipine GITS and ramipril on different estimates of BPV (24 h BPV, home BPV, and visit-to-visit BPV) in subjects with elevated BPV. The secondary objective is to assess whether the degree of treatment-induced changes in BPV, is related to the degree of regression (or progression) of organ damage, after accounting for mean BP reduction by treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, High Blood Pressure Variability
Keywords
Hypertension, Blood pressure variability, Home systolic blood pressure, Organ damage, Nifedipine GITS, Ramipril
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
168 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Nifedipine GITS 30 mg slow release
Arm Type
Experimental
Arm Description
Nifedipine GITS 30 mg slow release in tablets.
Arm Title
Ramipril 10 mg
Arm Type
Experimental
Arm Description
Ramipril 10 mg in tablets.
Intervention Type
Drug
Intervention Name(s)
Nifedipine GITS
Intervention Description
Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
Intervention Type
Drug
Intervention Name(s)
Ramipril
Intervention Description
Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
Primary Outcome Measure Information:
Title
Variability (standard deviation) of home systolic blood pressure at final visit
Time Frame
After 10 weeks of study treatment
Secondary Outcome Measure Information:
Title
Variability (standard deviation) of home diastolic blood pressure measured at final visit
Time Frame
At baseline and after 10 weeks of study treatment
Title
Short term 24h variability of systolic blood pressure at final visit (24h weighted standard deviation)
Time Frame
At baseline and after 10 weeks of study treatment
Title
Short term 24h variability of diastolic blood pressure at final visit (24h weighted standard deviation)
Time Frame
At baseline and after 10 weeks of study treatment
Title
Visit-to-visit variability (standard deviation) of systolic blood pressure assessed over the three last visits
Time Frame
At baseline and after 6, 8 and 10 weeks of study treatment
Title
Visit-to-visit variability (standard deviation) of diastolic blood pressure assessed over the three last visits
Time Frame
At baseline and after 6, 8 and 10 weeks of study treatment
Title
Mean 24 hour systolic blood pressure at final visit
Time Frame
At baseline and after 10 weeks of study treatment
Title
Mean 24 hour diastolic blood pressure at final visit
Time Frame
At baseline and after 10 weeks of study treatment
Title
Sokolow index at the end of the extension study
Time Frame
At baseline and after 12 months of study treatment
Title
Cornell voltage duration index at the end of the extension study
Time Frame
At baseline and after 12 months of study treatment
Title
Left ventricular mass index at the end of the extension study
Time Frame
At baseline and after 12 months of study treatment
Title
Microalbuminuria (albumin-creatinine ratio) at the end of the extension study
Time Frame
At baseline and after 12 months of study treatment
Title
Estimated glomerular filtration rate (eGFR, by CKD-EPI formula) at the end of the extension study
Time Frame
At baseline and after 12 months of study treatment
Title
Carotid-femoral pulse wave velocity (cfPWV) at the end of the extension study
Time Frame
At baseline and after 12 months of study treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female subjects
Age 35-75 years
Clinic systolic BP ≥140 mmHg and/or diastolic BP ≥ 90 mmHg (under no antihypertensive treatment)
Daytime BP on ambulatory BP monitoring (ABPM) ≥135 mmHg systolic and/or ≥85 mmHg diastolic (under no antihypertensive treatment)
Home SBP standard deviation (SD) >7 mmHg and/or daytime ambulatory SBP SD >12 mmHg
Patients may be included if untreated or, if treated with one antihypertensive drug or two drugs in low doses, after 2 weeks' washout period
Written informed consent to participate in the study
Exclusion Criteria:
Subjects treated with ≥ 2 antihypertensive drugs (except those on two drugs in low doses)
Treated subjects with on-treatment clinic BP ≥160 mmHg systolic and/or 100 mmHg diastolic
Treated antihypertensive subjects in whom withdrawal of treatment is deemed unethical by the investigator (e.g. because of the existence of compelling indications other than hypertension for continuous use of previously used antihypertensive agent)
Contraindications to study treatments as detailed in the relative Summaries of Medical Product Characteristics for ramipril (hypersensitivity to ramipril or any of the excipients or any other ACE inhibitor, history of angioneurotic oedema, extracorporeal treatments leading to contact of blood with negatively charged surfaces, significant bilateral renal artery stenosis or renal artery stenosis in a single functioning kidney, second and third trimesters of pregnancy, lactation, haemodynamically relevant renal artery stenosis, hypotensive or haemodynamically unstable patients) or nifedipine GITS (known hypersensitivity to nifedipine or to any of the excipients, pregnancy before week 20 and during breastfeeding, cardiovascular shock, concomitant treatment with rifampicin, patients with a Kock pouch)
Cardiovascular diseases other than hypertension (coronary heart disease, heart failure or left ventricular systolic dysfunction of any degree, atrial fibrillation or frequent arrhythmias, valvular or congenital heart disease, cardiomyopathies, cerebrovascular disease, peripheral artery disease, aortic aneurysm)
Chronic kidney disease
Suspected or confirmed secondary hypertension
Diabetes mellitus
Subjects with conditions other than those mentioned above, where compelling indications for the use of any specific class of antihypertensive medication exist, according to current (e.g. European Society of Cardiology) guidelines
Other conditions deemed relevant by the investigator (including respiratory disorders, liver disease, renal disease, thyroid disorders)
BMI ≥35 kg/m2
Known severe obstructive sleep apnea (apnea-hypopnea index > 30 or use of CPAP)
Premenopausal women not using effective contraceptive methods
Elevated probability of noncompliance with the study procedures
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gianfranco Parati, MD
Organizational Affiliation
Istituto Auxologico Italiano - Milan, Italy
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital Shanghai Institute of Hypertension, Shanghai Jiaotong University School of Medicine
City
Shanghai
Country
China
Facility Name
Hypertension Center, Third University Department of Medicine, Sotiria Hospital
City
Athens
Country
Greece
Facility Name
Istituto Auxologico Italiano
City
Milan
Country
Italy
12. IPD Sharing Statement
Citations:
PubMed Identifier
23817082
Citation
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc. No abstract available.
Results Reference
background
PubMed Identifier
23399972
Citation
Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol. 2013 Mar;10(3):143-55. doi: 10.1038/nrcardio.2013.1. Epub 2013 Feb 12. Erratum In: Nat Rev Cardiol. 2014 Jun;11(6):314.
Results Reference
background
PubMed Identifier
14508204
Citation
Liu JG, Xu LP, Chu ZX, Miao CY, Su DF. Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. J Hypertens. 2003 Oct;21(10):1961-7. doi: 10.1097/00004872-200310000-00025.
Results Reference
background
PubMed Identifier
20226988
Citation
Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010 Mar 13;375(9718):895-905. doi: 10.1016/S0140-6736(10)60308-X.
Results Reference
background
PubMed Identifier
20226989
Citation
Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010 Mar 13;375(9718):906-15. doi: 10.1016/S0140-6736(10)60235-8.
Results Reference
background
PubMed Identifier
24843686
Citation
Ushigome E, Fukui M, Hamaguchi M, Tanaka T, Atsuta H, Ohnishi M, Oda Y, Yamazaki M, Hasegawa G, Nakamura N. Beneficial effect of calcium channel blockers on home blood pressure variability in the morning in patients with type 2 diabetes. J Diabetes Investig. 2013 Jul 8;4(4):399-404. doi: 10.1111/jdi.12052. Epub 2013 Mar 4.
Results Reference
background
PubMed Identifier
24685006
Citation
Wang JG, Yan P, Jeffers BW. Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials. J Am Soc Hypertens. 2014 May;8(5):340-9. doi: 10.1016/j.jash.2014.02.004. Epub 2014 Feb 15.
Results Reference
background
PubMed Identifier
24671016
Citation
Levi-Marpillat N, Macquin-Mavier I, Tropeano AI, Parati G, Maison P. Antihypertensive drug classes have different effects on short-term blood pressure variability in essential hypertension. Hypertens Res. 2014 Jun;37(6):585-90. doi: 10.1038/hr.2014.33. Epub 2014 Mar 27.
Results Reference
background
PubMed Identifier
22499291
Citation
Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment. J Hypertens. 2012 Jun;30(6):1241-51. doi: 10.1097/HJH.0b013e32835339ac.
Results Reference
background
PubMed Identifier
22547439
Citation
Matsui Y, O'Rourke MF, Hoshide S, Ishikawa J, Shimada K, Kario K. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study. Hypertension. 2012 Jun;59(6):1132-8. doi: 10.1161/HYPERTENSIONAHA.111.189217. Epub 2012 Apr 30.
Results Reference
background
Learn more about this trial
REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial
We'll reach out to this number within 24 hrs